However, cancer cells develop innate or adaptive immune resistance and progress while being treated with anti-VEGF therapy or immune checkpoints inhibitors (ICIs), such as an anti-PD-1 antibody or an anti-CTLA4 antibody [3, 4]. This evidence concerns the gene PDCD1 and cancer.